Current status of ctDNA in precision oncology for hepatocellular carcinoma (vol 40, 140, 2021)

被引：5

作者：

Li, Yan ^{[1
,2
]}

Zheng, Yuanyuan ^{[2
]}

Wu, Liwei ^{[2
]}

Li, Jingjing ^{[2
]}

Ji, Jie ^{[2
]}

Yu, Qiang ^{[2
]}

Dai, Weiqi ^{[1
,2
]}

Feng, Jiao ^{[1
,2
]}

Wu, Jianye ^{[1
]}

Guo, Chuanyong ^{[1
,2
]}

机构：

[1] Tongji Univ, Putuo Peoples Hosp, Sch Med, Dept Gastroenterol, 1291 Jiangning Rd, Shanghai 200060, Peoples R China

[2] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Gastroenterol, 301 Middle Yanchang Rd, Shanghai 200072, Peoples R China

来源：

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2021年 / 40卷 / 01期

基金：

上海市自然科学基金; 中国国家自然科学基金;

关键词：

ctDNA; Hepatocellular carcinoma; Methylation; Mutation;

D O I：

10.1186/s13046-021-02032-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The conventional method used to obtain a tumor biopsy for hepatocellular carcinoma (HCC) is invasive and does not evaluate dynamic cancer progression or assess tumor heterogeneity. It is thus imperative to create a novel non-invasive diagnostic technique for improvement in cancer screening, diagnosis, treatment selection, response assessment, and predicting prognosis for HCC. Circulating tumor DNA (ctDNA) is a non-invasive liquid biopsy method that reveals cancer-specific genetic and epigenetic aberrations. Owing to the development of technology in next-generation sequencing and PCR-based assays, the detection and quantification of ctDNA have greatly improved. In this publication, we provide an overview of current technologies used to detect ctDNA, the ctDNA markers utilized, and recent advances regarding the multiple clinical applications in the field of precision medicine for HCC. © 2021, The Author(s).

引用

页数：1